Mol Genet Metab Rep. 2026 Oct 17;49:101369. doi: 10.1016/j.ymgmr.2026.101369. eCollection 2026 Dec.
ABSTRACT
BACKGROUND: Gaucher disease (GD) is a rare lysosomal disorder classified, on the basis of neurological involvement, into type 1 (GD1, non-neuronopathic) and types 2 (GD2) and 3 (GD3) (neuronopathic). Data on morbidity and mortality in Latin American cohorts remain scarce.
AIMS: To characterise morbidity and mortality patterns in a Brazilian GD cohort.
METHODS: Retrospective cohort study at a single GD referral centre in Porto Alegre, Brazil (2003-2023; n = 53; GD1 = 45, GD2 = 4, GD3 = 4). Diagnosis was molecularly confirmed by Sanger and massive parallel sequencing of GBA1. Comorbidities and causes of death were retrieved by chart review; survival was estimated by Kaplan-Meier analysis. Results: Median follow-up was 15 years. In GD1, comorbidities were predominantly psychiatric (71%), metabolic/endocrinological (69%) and cardiovascular (60%). Nine patients (17%) died: four GD1 patients (median age 65 years; three from malignancy, one from sepsis), all four GD2 patients (median age 5 months; respiratory or hepatic failure, sepsis) and one GD3 patient (Sudden Unexpected Death in Epilepsy at 27 years).
CONCLUSIONS: The phenotype-specific mortality pattern - malignancy as the leading cause of death in GD1, uniform early death in GD2 reflecting the disease's neurological trajectory rather than a failure of enzyme replacement therapy, and neurological death in GD3 - underscores the substantial burden of oncological, cardiovascular, metabolic and neurological comorbidities in this population and supports systematic multidisciplinary surveillance as a routine component of GD care in Brazil, even in resource-limited settings.
TAKE-HOME MESSAGE: Adult patients with Gaucher disease type 1 require close clinical monitoring for oncological, cardiovascular, metabolic and psychiatric comorbidities. Gaucher disease type 2 remains a devastating disease with a poor prognosis under current therapies.
PMID:42927298 | PMC:PMC13695159 | DOI:10.1016/j.ymgmr.2026.101369